These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

939 related items for PubMed ID: 19960016

  • 1. Discharge use of angiotensin receptor blockers provides comparable effects with angiotensin-converting enzyme inhibitors on outcomes in patients hospitalized for heart failure.
    Tsuchihashi-Makaya M, Furumoto T, Kinugawa S, Hamaguchi S, Goto K, Goto D, Yamada S, Yokoshiki H, Takeshita A, Tsutsui H, JCARE-CARD Investigators.
    Hypertens Res; 2010 Mar; 33(3):197-202. PubMed ID: 19960016
    [Abstract] [Full Text] [Related]

  • 2. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry.
    Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy CW, Young JB, OPTIMIZE-HF Investigators and Hospitals.
    J Am Coll Cardiol; 2007 Aug 21; 50(8):768-77. PubMed ID: 17707182
    [Abstract] [Full Text] [Related]

  • 3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep 21; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 4. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 21; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 5. Does aspirin use adversely influence intermediate-term postdischarge outcomes for hospitalized patients who are treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers? Findings from Organized Program to Facilitate Life-Saving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).
    Levy PD, Nandyal D, Welch RD, Sun JL, Pieper K, Ghali JK, Fonarow GC, Gheorghiade M, O'Connor CM.
    Am Heart J; 2010 Feb 21; 159(2):222-230.e2. PubMed ID: 20152220
    [Abstract] [Full Text] [Related]

  • 6. Atrial fibrillation and heart failure in cardiology practice: reciprocal impact and combined management from the perspective of atrial fibrillation: results of the Euro Heart Survey on atrial fibrillation.
    Nieuwlaat R, Eurlings LW, Cleland JG, Cobbe SM, Vardas PE, Capucci A, López-Sendòn JL, Meeder JG, Pinto YM, Crijns HJ.
    J Am Coll Cardiol; 2009 May 05; 53(18):1690-8. PubMed ID: 19406345
    [Abstract] [Full Text] [Related]

  • 7. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A, Divchev D, Luchtefeld M, Schieffer B.
    Minerva Cardioangiol; 2009 Dec 05; 57(6):773-85. PubMed ID: 19942847
    [Abstract] [Full Text] [Related]

  • 8. Prevalence, clinical characteristics, quality of life, and prognosis of patients with congestive heart failure and isolated left ventricular diastolic dysfunction.
    Badano LP, Albanese MC, De Biaggio P, Rozbowsky P, Miani D, Fresco C, Fioretti PM.
    J Am Soc Echocardiogr; 2004 Mar 05; 17(3):253-61. PubMed ID: 14981424
    [Abstract] [Full Text] [Related]

  • 9. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.
    Robles NR, Romero B, Fernandez-Carbonero E, Sánchez-Casado E, Cubero JJ.
    J Renin Angiotensin Aldosterone Syst; 2009 Dec 05; 10(4):195-200. PubMed ID: 20026868
    [Abstract] [Full Text] [Related]

  • 10. Optimization of heart FailUre medical Treatment after hospital discharge according to left ventricUlaR Ejection fraction: the FUTURE survey.
    Cohen Solal A, Leurs I, Assyag P, Beauvais F, Clerson P, Contre C, Thebaut JF, Genoun M, French National College of Cardiologists.
    Arch Cardiovasc Dis; 2012 Dec 05; 105(6-7):355-65. PubMed ID: 22800720
    [Abstract] [Full Text] [Related]

  • 11. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
    Sun SX, Ye X, Lee KY, Dupclay L, Plauschinat C.
    Clin Ther; 2008 Dec 05; 30 Pt 2():2217-27. PubMed ID: 19281916
    [Abstract] [Full Text] [Related]

  • 12. Meta-analysis of Renin-Angiotensin-aldosterone blockade for heart failure in presence of preserved left ventricular function.
    Meune C, Wahbi K, Duboc D, Weber S.
    J Cardiovasc Pharmacol Ther; 2011 Dec 05; 16(3-4):368-75. PubMed ID: 21193681
    [Abstract] [Full Text] [Related]

  • 13. Prospective evaluation of beta-blocker use at the time of hospital discharge as a heart failure performance measure: results from OPTIMIZE-HF.
    Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy CW, Young JB, OPTIMIZE-HF Investigators and Coordinators.
    J Card Fail; 2007 Nov 05; 13(9):722-31. PubMed ID: 17996820
    [Abstract] [Full Text] [Related]

  • 14. Effect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysis.
    McCall KL, Craddock D, Edwards K.
    Pharmacotherapy; 2006 Sep 05; 26(9):1297-306. PubMed ID: 16945052
    [Abstract] [Full Text] [Related]

  • 15. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction.
    Masoudi FA, Rathore SS, Wang Y, Havranek EP, Curtis JP, Foody JM, Krumholz HM.
    Circulation; 2004 Aug 10; 110(6):724-31. PubMed ID: 15289383
    [Abstract] [Full Text] [Related]

  • 16. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease.
    Berger AK, Duval S, Manske C, Vazquez G, Barber C, Miller L, Luepker RV.
    Am Heart J; 2007 Jun 10; 153(6):1064-73. PubMed ID: 17540211
    [Abstract] [Full Text] [Related]

  • 17. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes.
    Winkelmayer WC, Fischer MA, Schneeweiss S, Wang PS, Levin R, Avorn J.
    Am J Kidney Dis; 2005 Dec 10; 46(6):1080-7. PubMed ID: 16310574
    [Abstract] [Full Text] [Related]

  • 18. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.
    Circulation; 2009 Oct 20; 120(16):1577-84. PubMed ID: 19805651
    [Abstract] [Full Text] [Related]

  • 19. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure).
    van Veldhuisen DJ, Cohen-Solal A, Böhm M, Anker SD, Babalis D, Roughton M, Coats AJ, Poole-Wilson PA, Flather MD, SENIORS Investigators.
    J Am Coll Cardiol; 2009 Jun 09; 53(23):2150-8. PubMed ID: 19497441
    [Abstract] [Full Text] [Related]

  • 20. Patterns and predictors of evidence-based medication continuation among hospitalized heart failure patients (from Get With the Guidelines-Heart Failure).
    Krantz MJ, Ambardekar AV, Kaltenbach L, Hernandez AF, Heidenreich PA, Fonarow GC, Get With the Guidelines Steering Committee and Hospitals.
    Am J Cardiol; 2011 Jun 15; 107(12):1818-23. PubMed ID: 21482418
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.